Invokana: FDA Warnings on SGLT2 Diabetes Drugs
Sheller, P.C. attorneys are investigating the newer class of diabetes drugs following FDA warnings. ABOUT THE DRUGS Invokana (Invokamet) is a relatively new SGLT2 inhibitor diabetes drug that is intended to be used in combination with diet and exercise to improve glycemic control and lower blood sugar in adults with type 2 diabetes mellitus. When […]
$520 MILLION SETTLEMENT
April 27, 2010: In the third record whistleblower settlement for Sheller, P.C. in fifteen months, the firm represented a whistleblower who brought forth knowledge of wrongdoing by AstraZeneca. AstraZeneca agreed to a civil settlement of $520 million for charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement […]
In The New York Times: “Side Effects May Include Lawsuits”
One of the most-read articles in The New York Times regarding pharmaceutical drug product liability and whistleblower lawsuits quotes Stephen Sheller. Side Effects May Include Lawsuits BY DUFF WILSON NEW YORK – FOR decades, antipsychotic drugs were a niche product. Today, they’re the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion […]
